Earnings ·
Immuron Limited (NASDAQ: IMRN; ASX: IMC) reported FY26 global sales revenue of A$7.7 million, representing a 6%…
IMRNImmuron Ltd
Immuron Limited (NASDAQ: IMRN; ASX: IMC) reported FY26 global sales revenue of A$7.7 million, representing a 6% increase over the prior year. The company is shifting its strategy to partner clinical assets IMM-124E (Travelan) and IMM-529 (for Clostridioides difficile infection) for development and commercialization. IMM-529 has received FDA IND approval to proceed to Phase 2 clinical trials. IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA. Immuron is an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut-mediated diseases.